Alembic to demerge pharma business, clearing way for potential investors
This article was originally published in Scrip
The Indian generics company, Alembic, plans to demerge its pharmaceutical business into a separate entity as part of a revamp that will split its operations. The reorganisation aims to insulate the core pharma business from the more volatile penicillin G sector and to unlock value from Alembic's real estate assets.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.